First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Exclusion Criteria

• •Impaired cardiac function, clinically significant cardiac disease or cardiac arrhythmias
• •Pericarditis (any CTCAE grade) or pericardial effusion (CTCAE Grade ≥ 2)
• •Left Ventricular Ejection Fraction (LVEF) \< 50% (as measured at screening by echocardiogram).
• •History of anaphylactic reactions to monoclonal antibody therapy
• •History of Myelodysplastic syndrome (MDS)/treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML
• •Infections of CTCAE (Common Terminology Criteria for Adverse Events) version 5.0 Grade 2 not responding to therapy or active clinically serious infections of CTCAE Grade \>2; known human immunodeficiency virus (HIV) infection; active hepatitis B virus (HBV) or hepatitis C virus (HCV)infection requiring treatment. Patients with chronic HBV or HCV infection are eligible at the investigator's discretion provided that the disease is stable and sufficiently controlled under treatment
• •Known brain, spinal or meningeal metastases